Description and Brand Names
Drug information provided by: IBM Micromedex
US Brand Name
- Venclexta
Descriptions
Venetoclax is used alone or together with other medicines (eg, rituximab) to treat chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, in patients who have received at least one previous treatment. It is also used together with obinutuzumab to treat previously untreated CLL or SLL.
Venetoclax is also used together with other medicines (eg, azacitidine, decitabine, low-dose cytarabine) to treat newly-diagnosed acute myeloid leukemia (AML) in adults 75 years of age and older or who have other medical conditions that prevent the use of standard chemotherapy.
Venetoclax is an antineoplastic agent (cancer medicine). It interferes with the growth of cancer cells, which are eventually destroyed by the body.
This medicine is available only with your doctor's prescription.
This product is available in the following dosage forms:
Portions of this document last updated: July 01, 2020
Copyright © 2020 IBM Watson Health. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes.